Metagenomi (NASDAQ:MGX) Given New $14.00 Price Target at HC Wainwright

Metagenomi (NASDAQ:MGX) had its price objective hoisted by HC Wainwright from $7.00 to $14.00 in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

MGX has been the topic of several other research reports. BMO Capital Markets lowered their target price on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.67.

Metagenomi Stock Down 2.3 %

MGX stock opened at $3.86 on Tuesday. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $12.74. The firm’s 50-day simple moving average is $2.14 and its 200 day simple moving average is $3.30.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new stake in Metagenomi during the 2nd quarter worth about $26,000. BNP Paribas Financial Markets increased its stake in shares of Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after acquiring an additional 7,256 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Metagenomi in the 3rd quarter valued at about $33,000. XTX Topco Ltd bought a new stake in shares of Metagenomi in the 2nd quarter valued at about $66,000. Finally, Green Alpha Advisors LLC bought a new stake in shares of Metagenomi in the 3rd quarter valued at about $69,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.